Results 101 to 110 of about 22,911 (183)

Multicenter clinical evaluation of Etest meropenem-vaborbactam (bioMérieux) for susceptibility testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa [PDF]

open access: yes, 2019
Meropenem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults.
Davies, Leanne   +19 more
core   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

open access: yesBMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader   +4 more
doaj   +1 more source

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

open access: yesAntibiotics
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj   +1 more source

Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China

open access: yesBMC Microbiology
Purpose This nine-year (2016–2024) surveillance study aimed to investigate the molecular epidemiology and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales (CRE) in a tertiary hospital in Central China, with a focus on ...
Yungang Han   +12 more
doaj   +1 more source

Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections [PDF]

open access: yes
Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections.
Tout, M   +14 more
core   +1 more source

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents

open access: yesFrontiers in Microbiology
The global rise of multidrug-resistant bacteria necessitates the development of new antimicrobials and faster diagnostic tools. Conventional antimicrobial susceptibility testing is slow, relying on culture-based methods that delay effective treatment ...
Emily Salisbury   +13 more
doaj   +1 more source

EVALUATION OF THE MINIMUM INHIBITORY CONCENTRATION OF MEROPENEM AND NEW THERAPEUTIC OPTIONS FOR SERRATIA MARCESCENS AND MORGANELLACEAE ENTEROBACTERALES WITH REDUCED SUSCEPTIBILITY TO MEROPENEM

open access: yesBrazilian Journal of Infectious Diseases
Introduction/Objective: Serratia marcescens and Enterobacterales of the Morganellaceae family are associated with infections in different sites and exhibit an expected phenotype of resistance to several antimicrobials, making therapeutic options very ...
Lívia Medeiros   +5 more
doaj   +1 more source

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

open access: yes, 2017
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined ...
Debora Rubio-Aparicio   +6 more
core   +1 more source

Outline of Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacteriaceae

open access: yesInternational Journal of Pharmaceutical Sciences Review and Research, 2023
Dr. Kush Nimron, Dr. Johncy Nathasha
openaire   +1 more source

Home - About - Disclaimer - Privacy